Deals & Corporate Governance

  • January 22, 2025

    Vanda Loses Takings Clause Arguments In Trade Secret Fight

    A Court of Federal Claims judge has held that specifications on how fast Vanda Pharmaceuticals' drugs dissolve do not count as property interest under the Fifth Amendment, handing a loss to the pharmaceutical company in its trade secrets case against the federal government.

  • January 22, 2025

    Cooley-Led Insulin Device Maker Preps $113M IPO

    Insulin delivery system maker Beta Bionics on Wednesday announced the terms for its initial public offering, planning to raise $113 million.

  • January 21, 2025

    Cautious Optimism Permeates JPM Health Conference 2025

    Law360 Healthcare Authority talked with a dozen attorneys across seven firms during this year's J.P. Morgan Healthcare Conference to ask what they were hearing and how that could affect dealmaking for the rest of the year. Here's what we learned.

  • January 21, 2025

    Calif. Appeals Court Reinstates Nurses' Wage Suit

    A California appeals court upended a hospital operator's win on some claims in nurses' wage and hour lawsuit, saying the nurses put forward enough evidence to show their employer's rounding policy resulted in their underpayment.

  • January 17, 2025

    Law360 Names Practice Groups Of The Year

    Law360 would like to congratulate the winners of its Practice Groups of the Year awards for 2024, which honor the attorney teams behind litigation wins and significant transaction work that resonated throughout the legal industry this past year.

  • January 17, 2025

    Law360 Names Firms Of The Year

    Eight law firms have earned spots as Law360's Firms of the Year, with 54 Practice Group of the Year awards among them, steering some of the largest deals of 2024 and securing high-profile litigation wins, including at the U.S. Supreme Court.

  • January 17, 2025

    PE Firm Resolves FTC's Antitrust Anesthesia Roll-Up Case

    Private equity firm Welsh Carson Anderson & Stowe agreed to limit its involvement, entanglement and ownership rights with its portfolio company U.S. Anesthesia Partners Inc. to resolve allegations they engaged in a "roll-up" scheme to buy anesthesiology practices in Texas and drive up costs, the Federal Trade Commission said Friday.

  • January 17, 2025

    Crown Labs Tops Rival Bid In Quest To Buy Biotech Revance

    Skincare product company Crown Laboratories Inc. has offered to raise its all-cash bid to buy healthcare biotech company Revance Therapeutics Inc. from $3.10 per share to $3.65 per share as it seeks to beat out a surprise bid from a Revance shareholder, according to a securities filing on Friday. 

  • January 16, 2025

    EpiPen Direct Buyers, Mylan Ink $75M Antitrust Deal

    Mylan Pharmaceuticals has agreed to pay $73.5 million to resolve claims it worked with Pfizer to inflate the price of the latter's popular auto-injecting emergency allergy medication EpiPen, a proposed class of direct purchasers told a Kansas federal judge Wednesday, bringing the total settlement to $123.5 million.

  • January 15, 2025

    Del. Justices Mull 'Reasonable' Effort Duty In Drug Biz Deal

    An attorney for former stockholders of Ception Therapeutics Inc. told Delaware's top court on Wednesday that a now-retired vice chancellor "asked the wrong question" in dismissing a suit alleging breaches of an agreement to use commercially reasonable efforts before abandoning a new drug prospect.

  • January 14, 2025

    Healthcare Deals To Be More 'Rational' In 2025, Panel Says

    Healthcare deals will become more "rational" this year as buyers and sellers find more middle ground on valuations, experts said, potentially shaping a more optimistic landscape for transactions in the space.

  • January 14, 2025

    Fed. Circ. Judge Asks What's The Rush In Eylea Biosimilar Case

    Counsel for Amgen and a Federal Circuit judge got into a back-and-forth Tuesday concerning the pace of an appeal over a denied injunction on Regeneron's biosimilar of Eylea, with the judge wondering why the attorney was so eager to move things along.

  • January 14, 2025

    Chancery Hits Co. With $2.9M Atty Fee Bill As Sanction

    A California medical device molding company that sought millions from a merger partner for breaches of contract in Delaware's Court of Chancery came away Tuesday with awards of $104,000 for its claims and $2.9 million in attorney fees as a sanction for contempt and spoliation by Symbient Product Development LLC founder Scott Castanon.

  • January 14, 2025

    JPM Health Conference Days 1-2: What You Need To Know

    The J.P. Morgan Healthcare Conference kicked off in San Francisco, with surprisingly good weather and a handful of blockbuster announcements to open the industry's premier deals conference.

  • January 14, 2025

    MedQuest Adds Health System In-House Vet As Top Atty

    MedQuest Associates, an operator of outpatient diagnostic imaging facilities across the U.S., is welcoming a new chief legal officer who brings nearly three decades of experience working with healthcare organizations.

  • January 13, 2025

    Meet The Attorneys Advising Prospect Medical In Ch. 11

    A team of attorneys from Sidley Austin LLP is representing California-based hospital operator Prospect Medical Holdings Inc. in its Chapter 11 case in Texas, as the company aims to sell several facilities while refocusing on operations in its home state. 

  • January 13, 2025

    Proskauer Faces Revived DQ Bid In NJ Hospital Antitrust Fight

    CarePoint Health is once again pushing to have Proskauer Rose LLP disqualified as counsel for healthcare network RWJBarnabas Health Inc. in an antitrust lawsuit in New Jersey federal court, asserting that a magistrate judge erred in previously denying its request.

  • January 13, 2025

    Cravath-Led J&J Paying $14.6B For Neuropsychiatric Drug Co.

    Johnson & Johnson said Monday it has agreed to purchase Intra-Cellular Therapies Inc., a biopharmaceutical company focused on therapies for neuropsychiatric and neurological disorders, for approximately $14.6 billion.

  • January 10, 2025

    Taxation With Representation: Kirkland, Davis Polk, Wachtell

    In this week's Taxation With Representation, Constellation acquires Calpine, Cintas seeks a deal with UniFirst Corp., Stryker Corp. acquires Inari Medical Inc., and Paychex Inc. buys Paycor.

  • January 10, 2025

    BCLP's Global Healthcare Chair Jumps To Dechert

    Dechert LLP has brought on the former global chair of healthcare and life sciences at Bryan Cave Leighton Paisner LLP as a corporate and securities partner and leader of its healthcare regulatory practice.

  • January 09, 2025

    Amgen Says Enbrel Protected By Legit Patents, Rulings

    Amgen has asked a Virginia federal judge to permanently toss the latest version of a proposed class action accusing it of illegally entrenching and expanding patent rights to stave off cheaper competition for Enbrel, arguing the blockbuster arthritis treatment is protected by legitimate patents and court rulings of validity.

  • January 09, 2025

    Cancer Org Fails To Get Rival's TM Counterclaims Tossed

    A Georgia federal judge said Thursday that the Glioblastoma Foundation Inc. can't yet escape a series of counterclaims filed against it by a rival nonprofit amid a trademark spat, ruling that its defenses in a dismissal bid largely relied on factual issues about whether the rival fraudulently obtained the marks at issue.

  • January 09, 2025

    Yale Wins Info Battle In $435M Hospital Sale Contract Fight

    Three Connecticut property owners must hand over internal analyses and communications to Yale New Haven Health Services Corp. as it seeks evidence in support of its bid to back out of a $435 million deal to purchase hospitals from Prospect Medical Holdings Inc., a state court judge ruled.

  • January 08, 2025

    Colo. Judge Certifies National Class Of Senior Care Investors

    A Colorado federal judge on Wednesday certified a nationwide class of stockholders in a securities suit alleging a senior health care company made misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the falsehoods.

  • January 08, 2025

    Boston Scientific Paying Up To $664M For Bolt Medical

    Boston Scientific Corp. said Wednesday it plans to acquire the remaining stake it does not own in Bolt Medical Inc., the developer of a proprietary laser-based treatment for coronary and peripheral artery disease, for up to $664 million.

Expert Analysis

  • How 5 States' Deal Notification Laws Are Guiding Healthcare

    Author Photo

    Healthcare transaction notification laws at various stages of implementation in California, Illinois, Indiana, Oregon and Washington are shaping sector mergers and acquisitions, with significant transparency, continuity of care and compliance implications as providers tackle complex regulatory requirements, says Melesa Freerks at DLA Piper.

  • The Good, The Bad And The Ugly Of Healthcare's PE Boom

    Author Photo

    While an influx of capital may provide access to new resources and innovative technologies, the private equity model's method of funding may be fundamentally at odds with patient-first healthcare, and in recent years that inherent tension has gotten ugly, say Eva Gunasekera and Jaclyn Tayabji at Tycko & Zavareei.

  • High Court Made Profound Mistake In Tossing Purdue Deal

    Author Photo

    The U.S. Supreme Court's recent decision to throw out Purdue Pharma's Chapter 11 plan jeopardizes a multistate agreement that would provide approximately $7 billion in much-needed relief to help fight the opioid epidemic, with states now likely doomed to spend years chasing individual defendants across the globe, says Swain Wood at Morningstar.

  • After Chevron: Scale Tips Favor Away From HHS Agencies

    Author Photo

    The loss of Chevron deference may indirectly aid parties in challenging the U.S. Department of Health and Human Services' interpretations of regulations and could immediately influence several pending cases challenging HHS on technical questions and agency authority, say attorneys at Ropes & Gray.

  • After Chevron: FDA Regulations In The Crosshairs

    Author Photo

    The U.S. Supreme Court's overturning of the Chevron doctrine is likely to unleash an array of challenges against the U.S. Food and Drug Administration, focusing on areas of potential overreach such as the FDA's authority under the Federal Food, Drug and Cosmetic Act, say attorneys at Debevoise.

  • Navigating Scrutiny Of Friendly Professional Corps. In Calif.

    Author Photo

    In light of ongoing scrutiny and challenges to private equity participation in the California healthcare marketplace, particularly surrounding the use of the friendly professional corporation model, management services organizations should consider implementing four best practices, say attorneys at Holland & Knight.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy considers two recent decisions from the Third and Tenth Circuits, and identifies practice tips around class action settlements and standing in securities litigation.

  • The Current State Of Healthcare Transaction Reviews In Calif.

    Author Photo

    As of April, certain healthcare transactions in California have been subject to additional notification compliance requirements, and complying with these new rules could significantly delay and discourage some deals, says Andrew Demetriou at Husch Blackwell.

  • Careful Data Governance Is A Must Amid Enforcement Focus

    Author Photo

    Federal and state regulators' heightened focus on privacy enforcement, including the Federal Trade Commission's recent guidance on consumer protection in the car industry, highlight the importance of proactive risk management, compliance and data governance, say Jason Priebe and Danny Riley at Seyfarth.

  • 5 Steps To Navigating State Laws On Healthcare Transactions

    Author Photo

    As more states pass legislation requiring healthcare-transaction notice, private equity investors and other deal parties should evaluate the new laws and consider ways to mitigate their effects, say Carol Loepere and Nicole Aiken-Shaban at Reed Smith.

  • Feds' Biotech Enforcement Efforts Are Too Heavy-Handed

    Author Photo

    The U.S. Department of Justice's recent actions against biotech companies untether the Anti-Kickback Statute from its original legislative purpose, and threaten to stifle innovation and undermine patient quality of care, say attorneys at Ropes & Gray.

  • Del. Ruling Highlights M&A Deal Adviser Conflict Disclosures

    Author Photo

    The Delaware Supreme Court recently reversed the Court of Chancery's dismissal of challenges to Nordic Capital's acquisition of Inovalon, demonstrating the importance of full disclosure of financial adviser conflicts when a going-private merger seeks business judgment rule review, say attorneys at Debevoise.

  • A Recipe For Growth Equity Investing In A Slow M&A Market

    Author Photo

    Carl Marcellino at Ropes & Gray discusses the factors bolstering appetite for growth equity fundraising in a depressed M&A market, and walks through the deal terms and other ingredients that set growth equity transactions apart from bread-and-butter venture capital investing.